clinical trial · NCT06540391
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
Microbiotica Ltd·phase1·active not recruiting·n = 41
MelanomaMB097PembrolizumabVancomycin
brief summary
A Phase 1b study to evaluate the safety and tolerability of MB097 given in combination with pembrolizumab in patients with melanoma who demonstrate primary resistance to anti-PD1 therapy.
started
Aug 28, 2024
primary completion
Dec 1, 2025
completion
Aug 1, 2027
last updated
Sep 26, 2025
official title
A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination With Pembrolizumab in Melanoma Patients With Primary Resistance to an AntiPD1Containing Immunotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol